Related Experiment Video
Updated: Jan 6, 2026
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
Association between depression and metabolic dysfunction-associated steatotic liver disease: a cross-sectional
Florian Koutny1,2,3, Vanessa Frey4,5, Christian Datz6
1Karl Landsteiner University of Health Sciences, Vienna, Austria.
Background And Aims:
Depression is linked to obesity and metabolic syndrome, but its independent association with metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. We examined the association between depressive symptoms and MASLD, independent of other risk factors.
Methods:
We analyzed cross-sectional data from 7433 participants of the Paracelsus 10,000 study. Depression (BDI-II > 13) and MASLD (FLI ≥ 60 plus ≥ 1 cardiometabolic risk factor) were assessed. Associations were examined using Poisson and linear regression models adjusted for demographics, lifestyle factors, metabolic syndrome, and antidepressant use. Subgroup and interaction analyses explored effect modification.
Results:
MASLD was more prevalent in participants with depressive symptoms than those without (37% vs. 27%, p < 0.01). Depressive symptoms were independently associated with MASLD (adjusted incidence rate ratio: 1.25, 95% CI: 1.13-1.39, p < 0.01), with consistent findings using continuous BDI-II scores. The association remained robust across subgroups defined by age, metabolic syndrome, education, smoking status, and antidepressant use. No significant differences were observed in fibrosis markers (APRI and FIB-4).
Conclusion:
In this large, population-based cross-sectional study, depressive symptoms were found to be associated with MASLD, independent of metabolic risk factors and antidepressant use. However, given the observational design and limited detail on antidepressant type, dose, indication, and adherence, the findings should be interpreted with caution and do not support causal conclusions. Nevertheless, findings suggest that mental health considerations may be relevant in MASLD screening and prevention strategies. Further research is needed to explore whether and how antidepressant therapy may relate to liver health.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:19Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...